Mobile

A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase 3 Study to Assess the Efficacy and Safety of Vandetanib 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally...

Mise à jour : Il y a 4 ans
Référence :

A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase 3 Study to Assess the Efficacy and Safety of Vandetanib 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy

  • | Pays :
  • Belgium
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Critère d'inclusion

  • Differentiated thyroid cancer

Liens